Faron Pharmaceuticals Oy (LON:FARN) passed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $432.31 and traded as low as $410.00. Faron Pharmaceuticals Oy shares last traded at $430.00, with a volume of 30,737 shares traded.
The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 175.28. The firm has a market cap of $201.24 million and a price-to-earnings ratio of -3.93. The company has a 50 day moving average of GBX 432.31 and a 200 day moving average of GBX 377.04.
Faron Pharmaceuticals Oy Company Profile (LON:FARN)
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company in Finland. It has a pipeline of drug development projects focusing on acute organ traumas, vascular damage, and cancer immunotherapy. The company's lead product candidate is Traumakine, a recombinant human IFN beta-1a, which is in Phase III clinical trial for the treatment of acute respiratory distress syndrome (ARDS).
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.